CHIASMA INC Share · US16706W1027 · CHMA · A14WW4 (XNMS) — real-time quotes, company data, dividends, fundamentals, and AI-powered portfolio analysis on MoneyPeak
AI-Powered Analysis
Fundamental Analysis
Find out what the numbers really say — before the market does
Analyze now
News Sentiment
Are today's headlines a buy signal or a red flag?
Analyze now
Buy / Hold / Sell
Should you Buy, Hold, or Sell? Get the AI verdict now.
Analyze now
Risk Assessment
Uncover hidden risks before they hit your portfolio.
Analyze now
Fair Value
Is this stock cheap, fairly priced, or overvalued?
Analyze now
Latest AI Analyses of CHIASMA INC
No Price
Company Profile for CHIASMA INC Share
Chiasma, Inc., a clinical late-stage biopharmaceutical company, focuses on developing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease worldwide. The company develops oral octreotide capsules for adult patients under the MYCAPSSA name, which is in Phase III clinical trials for the treatment of acromegaly, a condition that results in the body's production of excess growth hormone. Chiasma, Inc. was founded in 2001 and is headquartered in Needham, Massachusetts.
Company Data
Name CHIASMA INC
Company Chiasma, Inc.
Symbol CHMA
Website
http://www.chiasma.com
Primary Exchange 
NASDAQ/NMS (GLOBAL MARKET)
NASDAQ/NMS (GLOBAL MARKET)
WKN A14WW4
ISIN US16706W1027
Asset Class Share
Sector Healthcare
Industry Biotechnology
CEO Raj Kannan
Country United States of America
Currency USD
Employees 0,1 T
Address 140 Kendrick Street, Building C East, 02451 Needham
IPO Date 2015-07-16
Ticker Symbols
| Name | Symbol |
|---|---|
| NASDAQ | CHMA |
More Shares
Investors who hold CHIASMA INC also have the following shares in their portfolio:
